Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $1.5 million.

  • Bolt Biotherapeutics' Accounts Payables rose 242.91% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 242.91%. This contributed to the annual value of $1.5 million for FY2024, which is 4954.8% down from last year.
  • As of Q3 2025, Bolt Biotherapeutics' Accounts Payables stood at $1.5 million, which was up 242.91% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Bolt Biotherapeutics' Accounts Payables registered a high of $5.2 million during Q3 2021, and its lowest value of $1.5 million during Q3 2024.
  • Its 5-year average for Accounts Payables is $2.8 million, with a median of $2.9 million in 2021.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 12365.46% in 2021, then crashed by 5975.01% in 2024.
  • Bolt Biotherapeutics' Accounts Payables (Quarter) stood at $3.6 million in 2021, then rose by 0.56% to $3.6 million in 2022, then fell by 16.89% to $3.0 million in 2023, then tumbled by 49.55% to $1.5 million in 2024, then grew by 0.73% to $1.5 million in 2025.
  • Its Accounts Payables was $1.5 million in Q3 2025, compared to $1.9 million in Q2 2025 and $1.5 million in Q1 2025.